Cybergenetics
Cybergenetics is a privately held Pittsburgh-based forensic technology company that develops TrueAllele®, a proprietary Bayesian probabilistic genotyping software used by 600+ law enforcement agencies across 48 US states and internationally to interpret complex DNA mixture evidence for criminal casework, exonerations, and retail loss prevention.
- Company typePrivate
- Founded1994
- HeadquartersPittsburgh, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Cybergenetics does
Cybergenetics is a privately held, founder-led forensic-technology company founded in 1994 and headquartered in Pittsburgh, Pennsylvania. The company develops and commercializes TrueAllele®, a proprietary probabilistic genotyping software platform that interprets complex DNA mixture data using fully-Bayesian algorithms. TrueAllele separates multi-contributor DNA samples (validated for up to 10 unknown contributors) into individual genotypes, computes likelihood ratios for match statistics, and reports match-error rates — addressing DNA evidence that crime laboratories routinely classify as "inconclusive," "too complex," or "uninterpretable."
The product portfolio spans four core forensics products (TrueAllele Casework, Database, Reference, and NGS), an investigative DNA database (TA-ID), and a commercial retail loss-prevention platform (ORCA). The technology is supported by 42+ peer-reviewed validation studies and has been admitted as reliable evidence in 50+ court decisions under Daubert and Frye standards, including a March 2026 Third Circuit ruling in USA v. Anderson. Cybergenetics has analyzed over 1,500 criminal cases across 600+ agencies in 48 US states plus federal, UK, Australian, and Canadian jurisdictions, and has contributed to 14–15 documented exonerations of wrongfully convicted individuals.
Cybergenetics monetizes through one-time/perpetual software licenses sold to government crime laboratories, per-case professional services (free screening followed by paid reports and expert testimony) to prosecutors, defense attorneys, investigators, and innocence projects, a subscription cloud platform (ORCA) for retail loss prevention, and prospective licensing of its algorithms into medical/clinical DNA computing. Go-to-market is direct enterprise field sales to government agencies combined with inside sales for case-based engagements and free DNA screening as a bottom-of-funnel conversion tool. The company is led by co-founders Dr. Mark W. Perlin (Chief Scientific and Executive Officer) and Dr. Ria David (President), with no disclosed venture or private equity backing.
Cybergenetics firmographics
Firmographics- Name
- Cybergenetics
- Legal name
- Cybergenetics
- Website
- https://cybgen.com
- Company type
- Private
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Cybergenetics is a privately held Pittsburgh-based forensic technology company that develops TrueAllele®, a proprietary Bayesian probabilistic genotyping software used by 600+ law enforcement agencies across 48 US states and internationally to interpret complex DNA mixture evidence for criminal casework, exonerations, and retail loss prevention.
- Ownership category
- akta.pro rank
Cybergenetics industry classification
Industry- Product category
- Forensic DNA Analysis Software
- NAICS
- Software Publishers (5132)
- SIC
- Services-Testing Laboratories (8734), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
- akta.pro secondary industry
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)
Keywords
Where Cybergenetics is headquartered
LocationHeadquarters
- HQ city
- Pittsburgh
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Cybergenetics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- TrueAllele Casework Software: Government crime laboratories purchase TrueAllele systems for DNA mixture interpretation. The software automates analysis workflows, reducing human involvement and analyst time while providing reliable DNA match statistics.
- DNA Analysis Services: Cybergenetics provides DNA analysis services consulting for prosecutors, defenders, investigators, and innocence groups on a case-by-case basis, including free screening followed by paid case reports and expert testimony
- ORCA Retail Crime DNA Platform: Cloud-based DNA intelligence platform for organized retail crime investigators and loss prevention professionals to identify perpetrators through crime scene DNA
- Medical/Clinical DNA Computing: Applying probabilistic genotyping algorithms to clinical medicine for cancer testing solutions and diagnostic data analysis
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Pay-as-you-go | Free TrueAllele Screening - initial DNA evidence evaluation |
| One time/ perpetual license | Multi-year contract | Crime Lab Software Licensing - TrueAllele Casework, Database, Reference products |
| Subscription | Annual | Commercial/Retail - ORCA DNA Intelligence Platform |
Go-to-market motion1 record
Distribution channels5 records
Marketing channels7 records
Cybergenetics product offering
Product offeringCore offering
Cybergenetics develops and licenses TrueAllele®, a fully automated probabilistic genotyping software that uses Bayesian probability models to separate complex DNA mixtures into individual contributor genotypes and produce quantitative match likelihood ratios. The technology transforms DNA evidence that crime labs deem 'inconclusive' or 'uninterpretable' into reliable identification information for prosecutors, defense attorneys, investigators, and innocence projects. Products span DNA mixture casework analysis, investigative databases, reference sample processing, NGS data interpretation, and a commercial retail crime DNA intelligence platform (ORCA).
Product overview
Cybergenetics offers TrueAllele®, a fully automated probabilistic genotyping technology platform that resolves complex DNA data for forensic identification. The product portfolio spans forensics, commercial retail, and medical applications. The forensics suite includes TrueAllele Casework for DNA mixture analysis in criminal cases, TrueAllele Database for evidence searching and matching, TrueAllele Reference for single-source DNA interpretation, and TrueAllele NGS for next-generation sequencing data analysis. TA-ID (TrueAllele Investigative Database) is a law enforcement investigative tool for generating leads from DNA evidence. ORCA extends TrueAllele technology into retail loss prevention. All products are powered by the core TrueAllele® probabilistic genotyping engine that extracts identification information from DNA data through Bayesian computing.
Differentiator
Problem solved
Functional benefit
Brands
- TrueAllele: Advanced probabilistic genotyping technology for DNA mixture analysis used in forensic science for criminal justice.
Products and services
- TrueAllele Casework
Quantifiable outcome
- False-positive rate of 0.005% compared to 2-6% for human manual analysis
- +3 more outcomes
Companies that use Cybergenetics
Customer profileNamed customers7 records
Segments7 records
Ideal customer profiles6 records
Cybergenetics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature10 records
Cybergenetics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Verogen (Illumina)notableTrueAllele Casework validated on the Verogen ForenSeq DNA Signature Prep Kit Primer Set B and MiSeq FGx for Next Generation Sequencing analysis. Integration allows NGS workflow data to be imported into the TrueAllele system for mixture interpretation.
Scale indicators16 records
Recent moves6 records
Expansion highlights6 records
Cybergenetics competitors and assessment
Company assessmentEmerging players
- GeneDx: GeneDx is a clinical genetic testing company that interprets NGS data at scale for diagnostic use cases including rare disease and hereditary cancer. It represents the broader clinical DNA interpretation market that Cybergenetics' medical computing initiative targets, making it a relevant emerging player in the same underlying technology domain.
- Niche Forensics: Niche Forensics provides forensic DNA software and consulting services including DNA interpretation tools for crime labs. It is a smaller emerging competitor in probabilistic genotyping interpretation, offering an alternative to TrueAllele for government crime lab customers.
Broad incumbents
- Promega: Promega is a major supplier of STR analysis kits (e.g., PowerPlex) and other forensic DNA reagents. While focused on reagents and kits rather than interpretation software, it sits in the same forensic DNA workflow and could expand into interpretation, making it a relevant adjacent incumbent.
- QIAGEN: QIAGEN provides sample preparation, PCR, and bioinformatics solutions for forensic and clinical DNA analysis. As a broad incumbent in molecular testing, it competes in adjacent workflow steps and could expand into DNA mixture interpretation, making it a relevant strategic peer to Cybergenetics.
- Bode Cellmark Forensics: Bode Cellmark Forensics provides forensic DNA testing services to law enforcement agencies, courts, and government labs. As a service provider complementing crime lab capabilities, it competes for outsourced DNA interpretation work similar to Cybergenetics' casework services.
- Thermo Fisher Scientific: Thermo Fisher supplies capillary electrophoresis instruments (e.g., 3500 Genetic Analyzer) and reagents used in forensic DNA workflows. As a broad incumbent in life-science tools, it could expand into probabilistic genotyping interpretation through internal development or acquisition, competing with TrueAllele across the workflow.
- IDEMIA (Identity & Security): IDEMIA provides biometric identification solutions including fingerprint, facial recognition, and related forensic identity infrastructure for governments. While not focused on DNA interpretation, it competes for the same government law enforcement and forensic budget allocations that fund Cybergenetics' customer purchases.
Others
- 23andMe: 23andMe is a consumer DNA testing company that processes large-scale genotyping data using Bayesian and statistical interpretation methods. While serving a consumer market rather than forensic casework, it shares underlying DNA interpretation technology concepts and represents the broader commercial DNA analytics ecosystem.
Direct peers
- STRmix: STRmix is a probabilistic genotyping software for DNA mixture interpretation developed by ESR (Institute of Environmental Science and Research) in New Zealand and commercialized internationally. It is the most direct head-to-head competitor to TrueAllele in separating mixed DNA samples and producing likelihood ratios for forensic casework.
- Verogen (Illumina): Verogen, now part of Illumina, provides the ForenSeq NGS kits and MiSeq FGx sequencing platform that TrueAllele NGS integrates with. While Verogen provides upstream DNA sample preparation and sequencing, it increasingly competes in end-to-end forensic interpretation workflows, making it a direct partner-competitor to Cybergenetics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Cybergenetics social profiles
Digital presenceCybergenetics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cybergenetics leadership team
Management profileNumber of profiles
Profiles2 records
Cybergenetics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cybergenetics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cybergenetics
What does Cybergenetics do?
Cybergenetics develops and licenses TrueAllele®, a fully automated probabilistic genotyping software that uses Bayesian probability models to separate complex DNA mixtures into individual contributor genotypes and produce quantitative match likelihood ratios. The technology transforms DNA evidence that crime labs deem 'inconclusive' or 'uninterpretable' into reliable identification information for prosecutors, defense attorneys, investigators, and innocence projects. Products span DNA mixture casework analysis, investigative databases, reference sample processing, NGS data interpretation, and a commercial retail crime DNA intelligence platform (ORCA).
Is Cybergenetics a public or private company?
Cybergenetics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Cybergenetics founded?
Cybergenetics was founded in 1994. It employs 11 to 50 people.
Where is Cybergenetics based?
Cybergenetics is headquartered in Pittsburgh, United States, in the North America region.
How does Cybergenetics make money?
Four revenue lines are on record. TrueAllele Casework Software is the primary driver. The others are DNA Analysis Services, ORCA Retail Crime DNA Platform and medical/Clinical DNA Computing.
Who are Cybergenetics's main competitors?
Emerging players on record are GeneDx and Niche Forensics. Broad incumbents are Promega, QIAGEN, Bode Cellmark Forensics, Thermo Fisher Scientific and IDEMIA (Identity & Security). 23andMe is listed as an others. Direct peers are STRmix and Verogen (Illumina).
Does Cybergenetics have an API?
No public API is recorded for Cybergenetics.
What industry is Cybergenetics in?
Cybergenetics's product category is Forensic DNA Analysis Software. Its primary akta.pro industry code is HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR), with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 5132 and its SIC code is 8734.